Enzalutamide + Placebo

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Progressive Metastatic Prostate Cancer

Conditions

Progressive Metastatic Prostate Cancer

Trial Timeline

Apr 23, 2014 → Jul 17, 2024

NCT ID

NCT02294461

About Enzalutamide + Placebo

Enzalutamide + Placebo is a phase 3 stage product being developed by Astellas Pharma for Progressive Metastatic Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02294461. Target conditions include Progressive Metastatic Prostate Cancer.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02677896	Phase 3	Completed	Mar 9, 2016	Jul 31, 2024	Metastatic Hormone Sensitive Prostate Cancer
NCT02528643	Phase 2	Completed	Nov 9, 2015	Feb 9, 2021	Advanced Hepatocellular Carcinoma
NCT02294461	Phase 3	Completed	Apr 23, 2014	Jul 17, 2024	Progressive Metastatic Prostate Cancer
NCT02003924	Phase 3	Completed	Oct 31, 2013	Nov 28, 2025	Nonmetastatic Castration-Resistant Prostate Cancer
NCT01212991	Phase 3	Completed	Sep 16, 2010	Feb 14, 2019	Prostate Cancer
NCT00974311	Phase 3	Completed	Sep 30, 2009	Nov 2, 2017	Castration-Resistant Prostate Cancer

Competing Products

20 competing products in Progressive Metastatic Prostate Cancer

See all competitors

Product	Company	Stage	Hype Score
AP01	Avalyn Pharmaceuticals	Phase 2	44
Enzalutamide	Astellas Pharma	Phase 2	52
dirucotide + Placebo	Eli Lilly	Phase 2/3	65
dirucotide	Eli Lilly	Phase 2/3	65
HRS-4357 injection + Enzalutamide；Abiraterone	Jiangsu Hengrui Medicine	Phase 3	77
ABBV-8E12 + Placebo solution for IV infusion on Day 15	AbbVie	Phase 2	52
Placebo + ABBV-8E12	AbbVie	Phase 2	52
ABBV-8E12	AbbVie	Phase 1	33
AZD4635 + Durvalumab + Cabazitaxel	AstraZeneca	Phase 2	52
antisense oligonucleotide + placebo	Novartis	Phase 1	33
Trametinib 2 mg	Novartis	Pre-clinical	23
Everolimus	Novartis	Phase 2	52
sunitinib + everolimus + chemotherapies recommended in france	Novartis	Pre-clinical	23
Remibrutinib (blinded) + Placebo + Remibrutinib (Open label)	Novartis	Phase 3	77
FTY720 + Placebo	Novartis	Phase 3	77
BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273	Novartis	Approved	85
Mayzent	Novartis	Pre-clinical	23
BAF312 + Placebo	Novartis	Phase 3	77
Tulmimetostat DL1 QD + Tulmimetostat DL2 QD + Tulmimetostat DL3 QD + Tulmimetostat Doses 1 or 2 QD + Tulmimetostat RP2D QD + JSB462 Dose 1 QD + JSB462 Dose 2 QD + JSB462 QD + Standard of Care (SoC)	Novartis	Phase 1/2	41
Imatinib mesylate	Novartis	Approved	85

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved

micafungin + voriconazoleApproved

mirabegron + solifenacinApproved

Zolpidem (Myslee®) + placeboApproved

TacrolimusApproved